Recent Quotes (30 days)

You have no recent quotes
chg | %

Obagi Medical Products, Inc.  

(Public, NASDAQ:OMPI)   Watch this stock  
Find more results for OMPI
Apr 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 10.70 - 25.60
Open     -
Vol / Avg. 0.00/1.33M
Mkt cap 418.07M
P/E 26.29
Div/yield     -
EPS 0.91
Shares 17.43M
Beta 1.20
Inst. own 76%

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin 23.98% 13.79%
Operating margin 39.30% 22.73%
EBITD margin - 24.58%
Return on average assets 38.05% 20.83%
Return on average equity 50.36% 27.11%
Employees 203 -
CDP Score - -


Suite 500, 3760 Kilroy Airport Way
United States - Map
+1-562-6281007 (Phone)
+1-562-6281008 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Obagi Medical Products, Inc. (Obagi) is a specialty pharmaceutical company that develops, markets and sells, and is a provider of, topical aesthetic and therapeutic prescription-strength skin care systems and related products in the physician-dispensed market. Obagi systems and products are designed to prevent and improve the common and visible skin disorders in adult skin, including premature aging, photodamage, hyperpigmentation (irregular or patchy discoloration of the skin), acne, sun damage, facial redness, and soft tissue deficits, such as fine lines and wrinkles. Obagi sells its products through a direct sales force in the United States and internationally through distribution partners in over 43 countries across North America, Central America, Europe, the Middle East and Asia. In April 2013, Valeant Pharmaceuticals International Inc acquired the entire share capital of Obagi Medical Products Inc.